CHARLOTTE, N.C. / Jan 04, 2024 / Business Wire / Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. The company’s formal presentation will begin at 11:15 a.m. PST (2:15 p.m. EST) and will include a question-and-answer session with the host analyst immediately following the conclusion of its presentation.
A link to the live audio webcast, as well as a replay of this event, will be available in the Investors section of the company’s website at www.investors.premierinc.com under Events and Presentations.
About Premier, Inc.
Premier, Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,350 U.S. hospitals and health systems and approximately 300,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com, as well as X, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.
Last Trade: | US$21.25 |
Daily Change: | 0.16 0.76 |
Daily Volume: | 1,313,661 |
Market Cap: | US$1.750B |
June 30, 2025 May 13, 2025 February 04, 2025 December 03, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load